Retroviral DNA integration requires the activity of at least one viral protein, the integrase (IN 
Retroviral DNA integration requires the activity of at least one viral protein, the integrase (IN) protein. We cloned and expressed the integrase gene of feline immunodeficiency virus (FIV) in Escherichia coli as a fusion to the malE gene and purified the IN fusion protein by affinity chromatography. The protein is active in site-specific cleavage of the viral DNA ends, DNA strand transfer, and disintegration. FIV IN has a relaxed viral DNA substrate requirement: it cleaves and integrates FIV DNA termini, human immunodeficiency virus DNA ends, and Moloney murine leukemia virus DNA ends with high efficiencies. In the cleavage reaction, IN exposes a specific phosphodiester bond near the viral DNA end to nucleophilic attack. In vitro, either H20, glycerol, or the 3' OH group of the viral DNA terminus can serve as nucleophile in this reaction. We found that FIV IN preferentially uses the 3' OH ends of the viral DNA as nucleophile, whereas HIV IN protein preferentially uses H20 and glycerol as nucleophiles.
Integration of a double-stranded DNA copy of the retroviral RNA into the DNA of the infected cell is essential for efficient replication of retroviruses. The following steps are involved in retroviral DNA integration (for recent reviews, see references 1, 5, 14, 15, 26, and 46) . After infection of a susceptible cell, the RNA of the virus is copied into a double-stranded, bluntended DNA molecule, a process catalyzed by the viral enzyme reverse transcriptase. A few nucleotides (generally two) are subsequently removed from the 3' ends of the viral DNA. After transfer to the nucleus, the newly generated viral 3' OH ends are coupled to phosphate groups in both strands of the host DNA. These phosphate groups are 4 to 6 bp apart from each other (43) . The non-base-pairing nucleotides at the 5' ends of the viral DNA (which flank the single-stranded gaps in the host DNA) are removed in a repair step that is presumably carried out by cellular enzymes. The single-stranded gaps are probably also filled in in this step. Finally, the integrated retrovirus (or provirus) has lost (in general) 2 bp from each end and is flanked by short, direct duplications of the target DNA. The length of these duplications is specific for the integrating retrovirus (43) . The proviral DNA is transcribed by host enzymes, and the resulting RNA is translated into protein or packaged into virions as new viral genomes. After budding from the cellular membrane, these virions can infect other permissive cells.
The only protein known to be required for integration is the viral integrase (IN) protein (6, 18, 19, 36) . Purified recombinant IN both specifically cleaves the viral DNA ends and couples these ends to target DNA (2, 6, 18) . Studies on human immunodeficiency virus type 1 (HIV-1) and HIV-2 IN have indicated that specific cleavage of the viral DNA termini (or donor cut) involves hydrolysis of the phosphodiester bond directly 3' of a conserved 5'-CA-3' sequence, resulting in release of a dinucleotide with a 5' phosphate and a 3' OH group (5' p-GT-OH 3' [10, 49] ). The integration or DNA strand transfer reaction also proceeds in one step; a phosphodiester bond in the target DNA is broken while a new one is made between viral and target DNA (10) . IN also possesses disintegration activity, which can be regarded as the reversal, in chemical terms, of the strand transfer reaction (4) .
Analyses of mutants of HIV-1, HIV-2, and Rous sarcoma virus IN have identified three distinct regions in the protein. (i) The N terminus may play a role in recognition of the viral DNA ends (40, 44) . (ii) The central region of the protein is conserved among all IN proteins and is also present in the transposases of several bacterial transposons (11, 20) . This region is sufficient to carry out disintegration, and therefore it probably contains the complete (and single) active site of IN (3, 45) . (iii) The C terminus of IN contains a DNA-binding domain; this domain binds both the viral DNA ends and nonspecific DNA with approximately equal affinity (32, 45, 51) , as does the full-length protein (20, 23, 27, 32, 39, 51) .
Both kinetic experiments (17) and in vitro complementation assays (9, 42) have indicated that the IN proteins are active as oligomers. Although IN forms predominantly dimers in solution (16, 17, 36, 24, 44) , it has not yet been established whether this is indeed the active oligomeric state of the protein.
The IN proteins of several retroviruses have been studied extensively. There are three main reasons why we set out to characterize the IN protein of feline immunodeficiency virus (FIV). (i) Solving the three-dimensional structure of (part of) the IN protein by X-ray analysis first requires that crystals of the protein be grown. To increase the chance of crystal formation, it is recommended that several IN proteins from various sources be studied. (ii) The FIV system is the smallest natural animal model for infections with lentiviruses and might therefore serve as an important model to test the effects of inhibitors of IN on infections with these retroviruses (8, 28 [38] are underlined and encode the N-terminal amino acid of IN [8] ) and AB3858 (5'-GTGCCCTGCAGTCACTCATCCCCTTCAGGAAGAG-3'; the underlined nucleotides are complementary to the stop codon of IN, positions 5240 to 5242 of the FIV sequence [38] ). These primers introduce unique BamHI (AB3857) and PstI (AB3858) restriction sites (in boldface) in the amplified fragment. As the template, we used total DNA of FIV producer cell line FL-4 (52) (kindly provided by A. Pfauth, The Netherlands Cancer Institute, Amsterdam). DNA was isolated as described by Miller et al. (25) . The PCR product was purified, digested with BamHI and PstI, and ligated into the BamHIand PstI-digested vector pMAL-c (New England Biolabs). In the resulting plasmid (pRP817), the FIV IN is fused at its 5' end to the 3' end of the Escherichia coli malE gene.
Expression and purification of the FIV IN fusion protein.
Construct pRP817 was introduced into E. coli JM101 (31 resulting strain was grown overnight at 37°C in LB medium (31) containing 50 ,ug of ampicillin per ml. The culture was diluted 1:100 in 150 ml of TB medium (31) with ampicillin and grown at 37°C to an optical density at 600 nm of 0.8. Protein production was induced by addition of isopropyl-p-D-thiogalactopyranoside (IPTG) to a final concentration of 0.3 mM. After 2.5 h, the bacteria were harvested by centrifugation and resuspended in 5 ml of 10 mM sodium phosphate (pH 7.2)-i M NaCl-1 mM EDTA-1 mM 3-mercaptoethanol-1 mg of lysozyme per ml. The suspension was sonicated and centrifuged for 20 min at 10,000 rpm in a Beckman HB-4 rotor. To the supernatant, 5 ml of 10 mM sodium phosphate (pH 7.2)-i mM EDTA-1 mM ,B-mercaptoethanol was added, and the material was loaded onto a 1.5-ml amylose column (New England Biolabs). The column was washed with 5 (38) , HIV-1 (50) , and MoMLV (37) . Only one of the two strands is shown. Nucleotides that are identical are boxed. The conserved 5'-CA-3' sequences (or complementary 5'-TG-3' sequences) are indicated in boldface.
U5 end TT 3 A (10 mM sodium phosphate [pH 7.2], 0.5 M NaCl, 1 mM EDTA, 1 mM ,-mercaptoethanol) supplemented with 0.25% Tween 20 and subsequently with 8 ml of buffer A. The maltose-binding protein (MBP)-IN fusion protein was eluted with 5 ml of buffer A containing maltose at 10 mM. Eight fractions of 0.5 ml were collected and analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. Peak fractions were pooled and concentrated three-to fourfold by dialysis to 10 mM Tris-HCl (pH 7.5)-0.5 M NaCl-0.5 mM EDTA-1 mM ,B-mercaptoethanol-40% glycerol. The protein was frozen in liquid nitrogen and stored at -70°C. Purification of the MBP-HIV-1 IN fusion protein has previously been described (22, 45) .
Cleavage, integration, and disintegration assays. The oligonucleotide substrates that were used in this study are listed in 5 mM MgCl2), 10% glycerol, 50 mM NaCl, 1 mM Tris, 50 ,uM EDTA, and 0.1 mM ,B-mercaptoethanol. Incubations were for 1 h at 30°C. Integration reaction mixtures were preincubated for 10 min at room temperature, after which 5 pmol of unlabeled nonspecific target DNA was added (a double-stranded oligonucleotide of the sequence 5'-GGGG TCCTATAGAAClTTlCCCACACTGT-3' and its complement). Reactions were stopped by addition of 10 pl. of formamide loading dye (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol) and analyzed by denaturing polyacrylamide gel electrophoresis followed by autoradiography.
Southwestern (DNA-protein) blot analysis. Southwestern blots were generated essentially as previously described (51 Fig. 2 . The proteins are approximately 37% identical. FIV IN contains two additional (Ser) residues at the N terminus but is nine amino acids shorter than the HIV-1 protein at the C terminus. The nine (additional) residues at the C terminus of HIV-1 IN can be deleted without effect on the activities of the protein in vitro (45) .
The MBP-FIV IN fusion was expressed, and purified by lysis of the bacteria in high salt, followed by affinity chromatography over an amylose resin column ( Fig. 3 ; see Materials and Methods). The purified protein, which has a molecular weight of approximately 73,000, was -80% pure, as judged from Coomassie blue-stained gels.
Cleavage of 5'-end-labeled substrates. Site-specific cleavage activity of the purified FIV IN fusion protein was tested on several radiolabeled oligonucleotide substrates (Fig. 1) . The substrates are identical in sequence to the viral DNA ends of FIV, HIV-1, and MoMLV and are labeled with 32P at the 5' ends of the strands that are expected to be cleaved by IN. The termini of the FIV DNA were predicted on the basis of similarity with the sequences of other retroviruses. As shown in Fig. 4A, FIV IN (6, 36) .
Although the FIV, HIV-1, and MoMLV substrates differ considerably in sequence (Fig. 4B) (47) . Similarly, the reactions with 20-bp FIV substrates and HIV-1 IN (Fig. 4A, lanes j and k) Interestingly, the HIV-1 IN protein cleaves both FIV substrates as efficiently as the HIV-1 U5 substrate but cleaves the MoMLV substrate rather poorly (Fig. 4A, lane m) , as has previously been described (39, 47) .
Cleavage of 3'-end-labeled substrates. To identify the products that are released from the viral DNA substrate during cleavage, we tested substrates that were radiolabeled within the dinucleotide portion at the 3' side of the IN cleavage site. Both an FIV and a HIV-1 U5 substrate were tested. Figure 5 shows that cleavage of these substrates by FIV IN in the presence of Mn2+ gives rise to one major product and two minor products. These different products have previously been identified in studies of HIV-1 IN as (i) a linear dinucleotide, which is released during hydrolysis of the phosphate group 3' of the conserved 5'-CA-3' sequence, (ii) a product in which glycerol is covalently coupled to the 3'-terminal dinucleotide via a 5' phosphodiester bond, and (iii) a circular dinucleotide, generated by nucleophilic attack of the 3' OH group of the viral DNA terminus at the target phosphate group (10, 49) .
FIV IN cleaves both the FIV and the HIV substrate in similar fashion (Fig. 5, lanes c and g) . The specific dinucleotide products, the linear form (D), the cyclic form (C), and the glycerol-derived product (G), are also indicated. Reaction products were separated on a denaturing 24% polyacrylamide gel. MoMLV (Fig. 6A) . FIV IN integrates both the FIV and HIV-1 substrates (Fig. 6A, lanes b and e) (Fig. 4) , FIV IN converts approximately 85% of the substrate into the specific recessed product, whereas in integration, less than 10% of the substrate is integrated into target DNA. In contrast, the activity of HIV-1 IN in integration (Fig. 6A, lane j) reflects its activity in donor cutting rather well: in both reactions, -50% of the substrate oligonucleotide is converted into product. As was the case for donor cutting, the integration activities of both FIV and HIV-1 IN are higher with the longer (26- An apparent discrepancy in the activities of the FIV IN protein is the high activity of the protein in site-specific cleavage and the relatively low activity in DNA strand transfer or integration. In site-specific cleavage, FIV (40) .
There are obvious differences between the in vitro conditions under which activity of IN is tested and the conditions under which IN is active in vivo. For instance, specific activity of FIV IN is detectable only in the presence of nonphysiological concentrations of Mn2+ (1 to 3 mM). In the integration reaction in vivo, IN will have to promote the concerted, pairwise integration of two viral DNA termini into target DNA in order to establish the proviral state. However, we were not able to detect these pairwise integration events with purified recombinant FIV IN, using both a PCR-based assay and a genetic integration assay (6, 12, 18, 46a) . Similar observations were made for the HIV-1 and HIV-2 IN proteins (for a review, see reference 46). It is possible that IN molecules and viral DNAs do not assemble properly in vitro or that additional proteins are required for either formation of proper nuclcoprotein complexes or stabilization of these complexes. Detailed molecular analysis of the complexes that are generated in vivo could clarify this.
